EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSNFUG00015009723
Gene Symbol: HTR1B
3 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b-Like

Ensembl ID : ENSNFUG00015012210
Gene Symbol: LOC107378215
3 Cross references
182 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSNFUG00015010433
Gene Symbol: HTR1F
3 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSNFUG00015007006
Gene Symbol: HTR2A
3 Cross references
217 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSNFUG00015006714
Gene Symbol: LOC107376997
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSNFUG00015025336
Gene Symbol: HTR2B
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSNFUG00015015300
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSNFUG00015015311
Gene Symbol: HTR3B
1 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSNFUG00015000208
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSNFUG00015007141
Gene Symbol: HTR6
1 Cross references
114 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSNFUG00015024411
Gene Symbol: LOC107387849
3 Cross references
344 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSNFUG00015003000
Gene Symbol: LOC107378566
3 Cross references
343 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).